CICC: Maintain Outperform rating on Sino Biopharmaceutical (01801.HK) and raise target price to HK$118.3.

According to the Economic Information APP, CICC released a research report stating that considering that Xinda Biotechnology (01801.HK) exceeded expectations for its operating profit in the first half of the year, it raised its net profit forecast for 2025 by 84.3% to 871 million yuan, while keeping the forecast for the mother net profit in 2026 unchanged at 1.3 billion yuan. The bank maintained an outperform rating, taking into account improvements in operational efficiency and progress in the innovation pipeline, and raised the target price by 24.1% to 118.3 Hong Kong dollars based on the DCF model, which represents a 30.0% upside potential from the current stock price.